(Total Views: 337)
Posted On: 04/13/2019 3:49:35 PM
Post# of 154961
Ok, thanks for finding that.
In the U.S., there are approximately 145,000 new cases of colon/rectal cancer each year. 25% of that is 36,250, assuming that intermediate and strong CCR5 expressers are treated.
Here are some quick revenue numbers based on 36,250 potential patients for colorectal cancer:
$120K per patient $4.35 billion
$100K per patient $3.625 billion
$75K per patient $2.7 billion
This is why we need to license HIV and the prostate cancer and get cancer trials moving. Of course this all hinges on leronlimab proving effective in human clinical trials.
In the U.S., there are approximately 145,000 new cases of colon/rectal cancer each year. 25% of that is 36,250, assuming that intermediate and strong CCR5 expressers are treated.
Here are some quick revenue numbers based on 36,250 potential patients for colorectal cancer:
$120K per patient $4.35 billion
$100K per patient $3.625 billion
$75K per patient $2.7 billion
This is why we need to license HIV and the prostate cancer and get cancer trials moving. Of course this all hinges on leronlimab proving effective in human clinical trials.
(0)
(0)
